GSK to acquire Chimagen Trispecific T-cell engager for multiple myeloma

GSK Plc

GSK plc (LON:GSK, NYSE: GSK) has announced it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) from Chimagen Biosciences (Chimagen), a privately held biotechnology company. GSK plans to develop and commercialise the asset for multiple myeloma, with the programme expected to enter phase I trials in 2027.

TCEs have shown transformational efficacy in multiple myeloma but have been associated with difficult tolerability profiles. The Chimagen trispecific asset is designed to address this by binding to T cells while simultaneously targeting two strategically selected and validated tumour-associated antigens. This targeted approach aims to achieve a deeper and more durable response compared to existing TCEs, along with an improved tolerability profile. This could enable broader adoption and earlier use in multiple myeloma treatment, providing an important advancement for patients who may require multiple options depending on their treatment needs. The US TCE market for multiple myeloma is expected to exceed $10 billion by 2032.[1]

Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “Today’s deal secures a promising T cell engager and advances GSK’s leadership goals in blood cancer. The agreement complements our existing portfolio in multiple myeloma, adding a new potential option to address the different needs of patients facing this complex disease.”

Zhenhao Zhou, Chief Executive Officer, Chimagen Biosciences, said: “Our mission has always been to translate cutting-edge innovation into life-changing medicines. Working with GSK combines our precision T-cell engager programme with their global development and commercial capabilities to redefine care for multiple myeloma patients. This agreement also marks another major milestone for our platforms as we continue to build an industry-leading pipeline of multi-specific antibody candidates.”

Multiple myeloma is the third most common blood cancer globally, with approximately 180,000 new cases diagnosed globally each year.[2],[3] While generally considered treatable, it is not currently curable, and research into new therapies is vital as the disease commonly becomes refractory to available treatments.[4]

The agreement builds on GSK’s existing relationship with Chimagen, following a previous agreement to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted TCE currently in phase I trials for B-cell malignancies and B-cell dependent autoimmune disorders.

Financial considerations

Under the terms of the agreement, GSK will pay an upfront fee to acquire full global rights to the TCE programme. Chimagen will also be eligible to receive success-based development and commercial milestone payments. The agreement has a total potential value of up to $750 million.

This agreement is subject to customary closing conditions.

[1] External commercial forecasts.

[2] Sung H, Ferlay J, Siegel R, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660.

[3] Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2016;43(6):676–681.doi: 10.1053/j.seminoncol.2016.11.004.

[4] Global Cancer Observatory. International Agency for Research on Cancer. World Health Organization. Multiple Myeloma fact sheet. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/35-multiple-myeloma-fact-sheet.pdf. Accessed 5 March 2025.

Share on:

Latest Company News

GSK secures positive EU recommendation for Bexsero Meningitis booster

GSK has received a positive recommendation from the EMA's CHMP for a Bexsero label update to include a single...

GSK reports 5% Q3 sales growth and reaffirms 2026 guidance

GSK reported third-quarter sales of £8.9 billion, up 5% at constant exchange rates, driven by 15% growth in Specialty...

GSK reports 62% response rate in ovarian cancer trial

GSK has reported a confirmed response rate of 62% for its investigational drug mocertatug rezetecan in patients with platinum-resistant...

GSK wins FDA approval for hepatitis B treatment Hibsago

GSK has received FDA approval for Hibsago (bepirovirsen), a new chronic hepatitis B treatment that achieved a 19% functional...

GSK reports positive global results for lung cancer drug candidate

GSK reports first global data for investigational antibody-drug conjugate risvutatug rezetecan, showing a confirmed objective response rate of 61%...

GSK to acquire Chimagen Trispecific T-cell engager for multiple myeloma

GSK has agreed to acquire global rights to Chimagen Biosciences’ trispecific T-cell engager for multiple myeloma in a deal...

    Search